Eniluracil 13C,15N2

Eniluracil 13C,15N2 is a chemical compound that is commonly used in the field of oncology. This compound is often used in combination with other drugs to help treat cancer patients. Eniluracil 13C,15N2 is a modified version of uracil, which is a key component in DNA and RNA synthesis. The modifications made to the structure of uracil in Eniluracil 13C,15N2 help to inhibit the activity of an enzyme called dihydropyrimidine dehydrogenase (DPD). DPD is responsible for breaking down uracil, which in turn can reduce the effectiveness of certain cancer treatments. Eniluracil 13C,15N2 works by inhibiting the activity of DPD, which can increase the effectiveness of certain chemotherapy drugs. This compound is often used in conjunction with 5-fluorouracil (5-FU), which is a common chemotherapy drug used to treat a variety of cancers. The combination of Eniluracil 13C,15N2 and 5-FU has been shown to be particularly effective in treating colorectal cancer. Eniluracil 13C,15N2 is a stable compound that is typically administered orally. This compound has been studied extensively in clinical trials, and has been shown to be generally well-tolerated by patients. Common side effects associated with Eniluracil 13C,15N2 include nausea, vomiting, and diarrhea. In rare cases, more serious side effects such as liver toxicity may occur. Overall, Eniluracil 13C,15N2 is a promising compound that has the potential to improve the effectiveness of certain cancer treatments.